The compound you're describing, **1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol**, is actually a **misnomer** and doesn't accurately represent a stable chemical structure. Here's why:
* **The nitro group and aziridine ring are incompatible:** Nitro groups (-NO2) are electron-withdrawing and highly reactive. Aziridine rings are strained three-membered rings with high reactivity. Placing these two functionalities in close proximity, as suggested in the name, would likely lead to a very unstable molecule that would quickly decompose.
* **Incorrectly assigned substituent positions:** The numbering system for the imidazole ring and the propanol backbone doesn't align with the typical naming conventions for these structures.
**Therefore, it's highly unlikely that this compound actually exists or has been researched.**
However, the description does point to potential research areas:
* **Nitroimidazoles:** These compounds are known for their antimicrobial activity and are used in medications to treat various infections.
* **Aziridines:** Aziridines are strained rings used in organic synthesis as building blocks and can be found in some biologically active molecules.
If you are interested in researching related compounds, you can explore the following:
* **Nitroimidazole derivatives:** Search for compounds with a nitroimidazole ring and different substituents attached.
* **Aziridine derivatives:** Explore compounds containing aziridine rings and their role in chemical synthesis and biological activity.
Remember to use proper chemical naming conventions and consult reliable scientific databases and literature for accurate information.
| ID Source | ID |
|---|---|
| PubMed CID | 119555 |
| CHEMBL ID | 1311017 |
| SCHEMBL ID | 10966055 |
| MeSH ID | M0142886 |
| Synonym |
|---|
| mls000766262 , |
| nsc600667 |
| NSC601351 , |
| 1-(2,3-dimethylaziridin-1-yl)-3-(2-nitroimidazol-1-yl)propan-2-ol |
| 1-(2,3-dimethyl-1-aziridinyl)-3-(2-(hydroxy(oxido)amino)-1h-imidazol-1-yl)-2-propanol |
| rsu 1164 |
| smr000528862 |
| 88876-94-2 |
| CHEMBL1311017 |
| HMS2885D12 |
| 1h-imidazole-1-ethanol, alpha-((2,3-dimethyl-1-aziridinyl)methyl)-2-nitro- |
| alpha-((2,3-dimethyl-1-aziridinyl)methyl)-2-nitro-1h-imidazole-1-ethanol |
| 1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol |
| SCHEMBL10966055 |
| 1-(2,3-dimethylaziridin-1-yl)-3-(2-nitro-1h-imidazol-1-yl)propan-2-ol |
| DTXSID701008545 |
| AKOS040753844 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Recently it has been shown that less toxic analogues of RSU 1069 can be produced by the introduction of alkyl substituents to moderate the reactivity of the aziridine function." | ( The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model. Siemann, DW, 1989) | 0.28 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Maximum tolerated single, intraperitoneal doses (MTD) were determined in C3H/He mice bearing subcutaneous KHT sarcomas, and a drug dose-response relationship for radiosensitization was established for each compound administered at the optimum time (45-60 min) before local irradiation of tumors with a 10-Gy dose of X-rays." | ( Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. Adams, GE; Cole, S; Fielden, EM; Jenkins, TC; Stratford, IJ, 1990) | 0.28 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 19.7077 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 28.1838 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 35.4813 | 1.1998 | 14.6419 | 50.1187 | AID488837 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 14.1254 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 3.5481 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (36.84) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.27) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||